Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;8(4):599–613. doi: 10.1111/j.1750-3639.1998.tb00187.x

p53 and Brain Tumors: From Gene Mutations to Gene Therapy

Giulia Fulci 1,2, Nobuaki Ishii 1, Erwin G Van Meir 1,2,✉
PMCID: PMC8098259  PMID: 9804370

Abstract

The p53 tumor suppressor gene (TP53) is the most frequently altered gene in human cancer and is also found mutated in several types of brain tumors. Loss of p53 function plays a central role in the development of cancer. The characterization of the biochemical pathways by which p53 alteration triggers tumorigenesis is the foundation for the design of novel therapeutic approaches.

Investigations of the intracellular mechanisms at the origin of p53 tumor suppressive functions have shown that p53 is a transcription factor able to sense a variety of cellular insults and induce a dual response: cell growth arrest/senescence or apoptosis. Less well studied are p53′s influences on extracellular events such as tumor angiogenesis, immunology and invasion. Here, we review these findings and specifically discuss their implications for brain tumor genesis, molecular diagnosis and prognosis. Of clinical importance are the findings that brain tumors with wild type (wt) or mutant p53 status may respond differently to radiation therapy and that novel therapeutic strategies using TP53 gene transfer or specifically targeting tumor cells with mutated p53 are being evaluated in clinical trials.

Full Text

The Full Text of this article is available as a PDF (157.9 KB).

References

  • 1. Aas AT , Tonnessen TI , Brun A , Salford LG ( 1995. ) Growth inhibition of rat glioma cells in vitro and in vivo by aspirin . J. Neuro-Oncol. 24 : 171 – 80 . [DOI] [PubMed] [Google Scholar]
  • 2. Agarwal ML , Agarwal A , Taylor WR , Stark GR ( 1995. ) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts . Proc. Natl. Acad. Sci. USA. 92 : 8493 – 7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Albertoni M , Daub DM , Arden KC , Viars CS , Powell C , Van Meir EG ( 1998. ) Genetic instability leads to loss of both p53 alleles in a human glioblastoma . Oncogene. 16 : 321 – 326 . [DOI] [PubMed] [Google Scholar]
  • 4. Ali IU , Schweitzer JB , Ikejiri B , Saxena A , Robertson JT , Oldfield EH ( 1994. ) Heterogeneity of subcellular localization of p53 protein in human glioblastomas . Cancer Res. 54 : 1 – 5 . [PubMed] [Google Scholar]
  • 5. Asai A , Miyagi Y , Sugiyama A , Gamanuma M , Hong SH , Takamoto S , Nomura K , Matsutani M , Takakura K , Kuchino Y ( 1994. ) Negative effects of wild‐type p53 and s‐Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy . J. Neuro-Oncol. 19 : 259 – 68 . [DOI] [PubMed] [Google Scholar]
  • 6. Avantaggiati ML , Ogryzko V , Gardner K , Giordano A , Levine AS , Kelly K ( 1997. ) Recruitment of p300/CBP in p53‐dependent signal pathways . Cell. 89 : 1175 – 84 . [DOI] [PubMed] [Google Scholar]
  • 7. Badie B , Drazan KE , Kramar MH , Shaked A , Black KL ( 1995. ) Adenovirus‐mediated p53 gene delivery inhibits 9L glioma growth in rats . Neuro. Res. 17 : 209 – 16 . [DOI] [PubMed] [Google Scholar]
  • 8. Baldwin NG , Rice CD , Tuttle TM , Bear HD , Hirsch JI , Merchant RE ( 1997. ) Ex vivo expansion of tumor‐draining lymph node cells using compounds which activate intra‐cellular signal transduction. I. Characterization and in vivo anti‐tumor activity of glioma‐sensitized lymphocytes . J. Neuro-Oncol. 32 : 19 – 28 . [DOI] [PubMed] [Google Scholar]
  • 9. Beckman WJ , Powers SK , Brown JT , Gillespie GY , Bigner DD , Camps JJ ( 1987. ) Differential retention of rhodamine 123 by avian sarcoma virus‐induced glioma and normal brain tissue of the rat in vivo . Cancer. 59 : 266 – 70 . [DOI] [PubMed] [Google Scholar]
  • 10. Benda P , Someda K , Messer J , Sweet WH ( 1971. ) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture . J. Neurosurg. 34 : 310 – 23 . [DOI] [PubMed] [Google Scholar]
  • 11. Benhattar J , Cerottini JP , Saraga E , Metthez G , Givel JC ( 1996. ) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int . J. Cancer. 69 : 190 – 2 . [DOI] [PubMed] [Google Scholar]
  • 12. Bergh J , Norberg T , Sjogren S , Lindgren A , Holmberg L ( 1995. ) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy . Nat. Med. 1 : 1029 – 34 . [DOI] [PubMed] [Google Scholar]
  • 13. Bertrand P , Rouillard D , Boulet A , Levalois C , Soussi T , Lopez BS ( 1997. ) Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein . Oncogene. 14 : 1117 – 1122 . [DOI] [PubMed] [Google Scholar]
  • 14. Bögler O , Huang HJS , Cavenee WK ( 1995. ) Loss of wild‐type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation . Cancer Res. 55 : 2746 – 51 . [PubMed] [Google Scholar]
  • 15. Bögler O , Huang HJS , Kleihues P , Cavenee WK ( 1995. ) The p53 gene and its role in human brain tumors . Glia. 15 : 308 – 27 . [DOI] [PubMed] [Google Scholar]
  • 16. Boulikas T ( 1996. ) Liposome DNA delivery and uptake by cells . Oncol. Rep. 3 : 989 – 995 . [DOI] [PubMed] [Google Scholar]
  • 17. Brown CR , Doxsey SJ , White E , Welch WJ ( 1994. ) Both viral (adenovirus E 1B) and cellular (hsp 70, p53) components interact with centrosomes . J. Cell Physiol. 160 : 47 – 60 . [DOI] [PubMed] [Google Scholar]
  • 18. Caelles C , Helmberg A , Karin M ( 1994. ) p53‐dependent apoptosis in the absence of transcriptional activation of p53‐target genes . Nature. 370 : 220 – 3 . [DOI] [PubMed] [Google Scholar]
  • 19. Chen J , Willingham T , Shuford M , Bruce D , Rushing E , Smith Y , Nisen PD ( 1996. ) Effects of ectopic overexpression of p21(WAF1/CIP1)on aneuploidy and the malignant phenotype of human brain tumor cells . Oncogene. 13 : 1395 – 403 . [PubMed] [Google Scholar]
  • 20. Chen Y , Chen PL , Lee WH ( 1994. ) Hot‐spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle . Mol. Cell. Biol. 14 : 6764 – 72 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Cho Y , Gorina S , Jeffrey PD , Pavletich NP ( 1994. ) Crystal structure of a p53 tumor suppressor‐DNA complex: understanding tumorigenic mutations . Science. 265 : 346 – 355 . [DOI] [PubMed] [Google Scholar]
  • 22. Crafts D , Wilson CB ( 1977. ) Animal models of brain tumors . Natl. Cane. Inst. Mon. 46 : 11 – 7 . [PubMed] [Google Scholar]
  • 23. Cross SM , Sanchez CA , Morgan CA , Schimke MK , Ramel S , Idzerda RL , Raskind WH , Reid BJ ( 1995. ) A p53‐dependent mouse spindle checkpoint . Science. 267 : 1353 – 6 . [DOI] [PubMed] [Google Scholar]
  • 24. Dameron KM , Volpert OV , Tainsky MA , Bouck N ( 1994. ) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin‐1 . Science. 265 : 1582 – 4 . [DOI] [PubMed] [Google Scholar]
  • 25. Davis FG , Preston‐Martin S ( 1998. ) Epidemiology . In : RUSSELL AND RUBINSTEIN'S Pathology of Tumors of the Nervous Sytem , Bigner DD, McLendon RE, Bruner JM , 17 – 33 , London .
  • 26. Denissenko MF , Pao A , Tang M , Pfeifer GP ( 1996. ) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 . Science. 274 : 430 – 2 . [DOI] [PubMed] [Google Scholar]
  • 27. Di Leonardo A , Khan SH , Linke SP , Greco V , Seidita G , Wahl GM ( 1997. ) DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function . Cancer Res. 57 : 1013 – 1019 . [PubMed] [Google Scholar]
  • 28. Di Leonardo A , Linke SP , Clarkin K , Wahl GM ( 1994. ) DNA damage triggers a prolonged p53‐dependent G1 arrest and long‐term induction of Cip 1 in normal human fibroblasts . Genes Develop. 8 : 2540 – 51 . [DOI] [PubMed] [Google Scholar]
  • 29. Dittmer D , Pati S , Zambetti G , Chu S , Teresky AK , Moore M , Finlay C , Levine AJ ( 1993. ) Gain of function mutations in p53 . Nature Genet. 4 : 42 – 46 . [DOI] [PubMed] [Google Scholar]
  • 30. El‐Deiry WS , Tokino T , Velculescu VE , Levy DB , Parsons R , Trent JM , Lin D , Mercer WE , Kinzler KW , Vogelstein B ( 1993. ) WAF 1, a potential mediator of p53 suppression . Cell. 75 : 817 – 825 . [DOI] [PubMed] [Google Scholar]
  • 31. Fujiwara T , Mukhopadhyay T , Cai DW , Morris DK , Roth JA , Grimm EA ( 1994. ) Retroviral‐mediated transduction of p53 gene increases TGF‐beta expression in a human glioblastoma cell line . Int. J. Cancer. 56 : 834 – 9 . [DOI] [PubMed] [Google Scholar]
  • 32. Fukasawa K , Choi T , Kuriyama R , Rulong S , Vande Woude G ( 1996. ) Abnormal centrosome amplification in the absence of p53 . Science. 271 : 1744 – 7 . [DOI] [PubMed] [Google Scholar]
  • 33. Goh HS , Yao J , Smith DR ( 1995. ) p53 point mutation and survival in colorectal cancer patients . Cancer Res. 55 : 5217 – 21 . [PubMed] [Google Scholar]
  • 34. Greenblatt MS , Bennett WP , Hollstein M , Harris CC ( 1994. ) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res. 54 : 4855 – 78 . [PubMed] [Google Scholar]
  • 35. Haas‐Kogan D , Yount G , Haas M , Levi D , Kogan SS , Hu L , Vidair C , Deen DF , Dewey WC , Israel MA ( 1996. ) p53‐dependent G1 arrest and p53‐independent apoptosis influence the radiobiologic response of glioblastoma . Int. J. Radiat. Onco.I Biol. Phys. 36 : 95 – 103 . [DOI] [PubMed] [Google Scholar]
  • 36. Hainaut P , Soussi T , Shomer B , Hollstein M , Greenblatt M , Hovig E , Harris CC , Montesano R ( 1997. ) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects . Nucl. Ac. Res. 25 : 151 – 7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Harper JW , Adami GR , Wei N , Keyomarsi K , Elledge SJ ( 1993. ) The p21 Cdk‐interacting protein is a potent inhibitor of G1 cyclin‐dependent kinases . Cell. 75 : 805 – 816 . [DOI] [PubMed] [Google Scholar]
  • 38. Harvey M , Vogel H , Morris D , Bradley A , Bernstein A , Donehower LA ( 1995. ) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53‐deficient mice . Nature Genet. 9 : 305 – 11 . [DOI] [PubMed] [Google Scholar]
  • 39. Haupt Y , Barak Y , Oren M ( 1996. ) Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2 . EMBO J. 15 : 1596 – 606 . [PMC free article] [PubMed] [Google Scholar]
  • 40. Haupt Y , Rowan S , Oren M ( 1995. ) p53‐mediated apoptosis in HeLa cells can be overcome by excess pRB . Oncogene. 10 : 1563 – 71 . [PubMed] [Google Scholar]
  • 41. Hayashi Y , Yamashita J , Yamaguchi K ( 1991. ) Timing and role of p53 gene mutation in the recurrence of glioma . Biochem. Biophys. Res. Comm. 180 : 1145 – 1150 . [DOI] [PubMed] [Google Scholar]
  • 42. Heise C , Sampson‐Johannes A , Williams A , McCormick F , Von Hoff D , Kirn DH ( 1997. ) ONYX‐015, an E 1B geneattenuated adenovirus, causes tumor‐specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents . Nat. Med. 3 : 639 – 45 . [DOI] [PubMed] [Google Scholar]
  • 43. Hiraga S , Arita N , Ohnishi T , Izumoto S , Taki T , Higuchi M , Iwaisako K , Sakoda S , Yamamoto Y , Hayakawa T ( 1996. ) Establishment of spontaneously immortalized rat type 1 astroglial cell lines: the role of p53 in astroglial carcinogenesis . Glia. 18 : 185 – 99 . [DOI] [PubMed] [Google Scholar]
  • 44. Hiraga S , Arita N , Ohnishi T , Izumoto S , Taki T , Yamamoto H , Higuchi M , Hayakawa T ( 1995. ) Transformation of type 1 astrocytes with N‐ethyl‐N‐nitrosourea: establishment of an in vitro system and the role of the p53 gene . Glia. 13 : 51 – 63 . [DOI] [PubMed] [Google Scholar]
  • 45. Hollstein M , Shomer B , Greenblatt M , Soussi T , Hovig E , Montesano R , Harris CC ( 1996. ) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation . Nucl. Ac. Res. 24 : 141 – 6 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Horio Y , Takahashi T , Kuroishi T , Hibi K , Suyama M , Niimi T , Shimokata K , Yamakawa K , Nakamura Y , Ueda R , et al ( 1993. ) Prognostic significance of p53 mutations and 3p deletions in primary resected non‐small cell lung cancer . Cancer Res. 53 : 1 – 4 . [PubMed] [Google Scholar]
  • 47. Hsiao M , Tse V , Carmel J , Costanzi E , Strauss B , Haas M , Silverberg GD ( 1997. ) Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity . Biochem. Biophys. Res. Comm. 233 : 329 – 35 . [DOI] [PubMed] [Google Scholar]
  • 48. Hsiao M , Tse V , Carmel J , Tsai Y , Feigner PL , Haas M , Silverberg GD ( 1997. ) Intracavitary liposome‐mediated p53 gene transfer into glioblastoma with endogenous wild‐type p53 in vivo results in tumor suppression and long‐term survival . Biochem. Biophys. Res. Comm. 233 : 359 – 364 . [DOI] [PubMed] [Google Scholar]
  • 49. Imamura J , Bartram CR , Berthold F , Harms D , Nakamura H , Koeffler HP ( 1993. ) Mutation of the p53 gene in neuroblastoma and its relationship with N‐myc amplification . Cancer Res. 53 : 4053 – 8 . [PubMed] [Google Scholar]
  • 50. Iwadate Y , Fujimoto S , Tagawa M , Namba H , Sueyoshi K , Hirose M , Sakiyama S ( 1996. ) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas . Int. J. Cancer. 69 : 236 – 40 . [DOI] [PubMed] [Google Scholar]
  • 51. Jung JM , Li H , Kobayashi T , Kyritsis AP , Langford LA , Bruner JM , Levin VA , Zhang W ( 1995. ) Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53 . Cell Growth Differ. 6 : 909 – 13 . [PubMed] [Google Scholar]
  • 52. Kieser A , Weich HA , Brandner G , Marme D , Kolch W ( 1994. ) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression . Oncogene. 9 : 963 – 9 . [PubMed] [Google Scholar]
  • 53. Kleihues P , Aguzzi A , Ohgaki H ( 1995. ) Genetic and environmental factors in the etiology of human brain tumors . Toxicol. Lett. 3 : 601 – 605 . [DOI] [PubMed] [Google Scholar]
  • 54. Kleihues P , Ohgaki H , Eibl RH , Reichel MB , Mariani L , Gehring M , Petersen I , Holl T , von Deimling A , Wiestler OD , et al. ( 1994. ) Type and frequency of p53 mutations in tumors of the nervous system and its coverings . Recent Results Cancer Res. 135 : 25 – 31 . [DOI] [PubMed] [Google Scholar]
  • 55. Kleihues P , Schauble B , zur Hausen A , Esteve J , Ohgaki H ( 1997. ) Tumors associated with p53 germline mutations: a synopsis of 91 families . Am. J. Pathol. 150 : 1 – 13 . [PMC free article] [PubMed] [Google Scholar]
  • 56. Ko LJ , Prives C ( 1996. ) P53 ‐ Puzzle and Paradigm . Genes Develop. 10 : 1054 – 1072 . [DOI] [PubMed] [Google Scholar]
  • 57. Köck H , Harris MP , Anderson SC , Machemer T , Hancock W , Sutjipto S , Wills KN , Gregory RJ , Shepard HM , Westphal M , Maneval DC ( 1996. ) Adenovirus‐mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo . Int. J. Cancer. 67 : 808 – 15 . [DOI] [PubMed] [Google Scholar]
  • 58. Kondo S , Barna BP , Kondo Y , Tanaka Y , Casey G , Liu J , Morimura T , Kaakaji R , Peterson JW , Werbel B , Barnett GH ( 1996. ) WAF1/CIP1 increases the susceptibility of p53 non‐functional malignant glioma cells to cisplatin‐induced apoptosis . Oncogene. 13 : 1279 – 85 . [PubMed] [Google Scholar]
  • 59. Kyritsis AP , Yung WK , Leeds NE , Bruner J , Gleason MJ , Levin VA ( 1992. ) Multifocal cerebral gliomas associated with secondary malignancies . Lancet. 339 : 1229 – 30 . [DOI] [PubMed] [Google Scholar]
  • 60. Levine AJ ( 1997. ) p53, the cellular gatekeeper for growth and division . Cell. 88 : 323 – 31 . [DOI] [PubMed] [Google Scholar]
  • 61. Li HW , Lochmuller H , Yong VW , Karpati G , Nalbantoglu J ( 1997. ) Adenovirus‐mediated wild‐type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J. Neuropath . Exp. Neur. 56 : 872 – 878 . [DOI] [PubMed] [Google Scholar]
  • 62. Li J , Hu SX , Perng GS , Zhou Y , Xu K , Zhang C , Seigne J , Benedict WF , Xu HJ ( 1996. ) Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro . Oncogene. 13 : 2379 – 86 . [PubMed] [Google Scholar]
  • 63. Lin D , Shields MT , Ullrich SJ , Appella E , Mercer WE ( 1992. ) Growth arrest induced by wild‐type p53 protein blocks cells prior to or near the restriction point in late G1 phase . Proc. Natl. Acad. Sci. USA. 89 : 9210 – 4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Livingstone LR , White A , Sprouse J , Livanos E , Jacks T , Tlsty TD ( 1992. ) Altered cell cycle arrest and gene amplification potential accompany loss of wild‐type p53 . Cell. 70 : 923 – 35 . [DOI] [PubMed] [Google Scholar]
  • 65. Lotem J , Sachs L ( 1995. ) A mutant p53 antagonizes the deregulated c‐myc‐mediated enhancement of apoptosis and decrease in leukemogenicity . Proc. Natl. Acad. Sci. USA. 92 : 9672 – 6 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Lowe SW , Bodis S , McClatchey A , Remington L , Ruley HE , Fisher DE , Housman DE , Jacks T ( 1994. ) p53 status and the efficacy of cancer therapy in vivo . Science. 266 : 807 – 10 . [DOI] [PubMed] [Google Scholar]
  • 67. Lubin R , Schlichtholz B , Bengoufa D , Zalcman G , Tredaniel J , Hirsch A , De Fromentel CC , Preudhomme C , Fenaux P , Fournier G , et al ( 1993. ) Analysis of p53 antibodies in patients with various cancers define B‐cell epitopes of human p53: distribution on primary structure and exposure on protein surface . Cancer Res. 53 : 5872 – 6 . [PubMed] [Google Scholar]
  • 68. Lubin R , Zalcman G , Bouchet L , Tredanel J , Legros Y , Cazals D , Hirsch A , Soussi T ( 1995. ) Serum p53 antibodies as early markers of lung cancer . Nat. Med. 1 : 701 – 2 . [DOI] [PubMed] [Google Scholar]
  • 69. Ludes MJ , Subler MA , Shivakumar CV , Munoz RM , Jiang P , Bigger JE , Brown DR , Deb SP , Deb S ( 1996. ) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 . Mol. Cell. Biol. 16 : 6009 – 19 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Margulies L , Sehgal PB ( 1993. ) Modulation of the human interleukin‐6 promoter (IL‐6) and transcription factor C/EBP beta (NF‐IL6) activity by p53 species . J. Biol. Chem. 268 : 15096 – 100 . [PubMed] [Google Scholar]
  • 71. Marks DI , Kurz BW , Link MP , Ng E , Shuster JJ , Lauer SJ , Carroll D , Brodsky I , Haines DS ( 1997. ) Altered expression of p53 and mdm‐2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia . J. Clin. Oncol. 15 : 1158 – 62 . [DOI] [PubMed] [Google Scholar]
  • 72. Martin HM , Filipe MI , Morris RW , Lane DP , Silvestre F ( 1992. ) p53 expression and prognosis in gastric carcinoma . Int. J. Cancer. 50 : 859 – 62 . [DOI] [PubMed] [Google Scholar]
  • 73. Mayordomo JI , Loftus DJ , Sakamoto H , De Cesare CM , Appasamy PM , Lotze MT , Storkus WJ , Appella E , DeLeo AB ( 1996. ) Therapy of murine tumors with p53 wild‐type and mutant sequence peptide‐based vaccines . J. Exp. Med. 183 : 1357 – 65 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Mekeel KL , Tang W , Kachnic LA , Luo CM , Defrank JS , Powell SN ( 1997. ) Inactivation of p53 results in high rates of homologous recombination . Oncogene. 14 : 1847 – 1857 . [DOI] [PubMed] [Google Scholar]
  • 75. Mercer WE , Shields MT , Amin M , Sauve GJ , Appella E , Romano JW , Ullrich SJ ( 1990. ) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild‐type p53 . Proc. Natl. Acad. Sci. USA. 87 : 6166 – 6170 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Mercer WE , Shields MT , Lin D , Appella E , Ullrich SJ ( 1991. ) Growth suppression induced by wild‐type p53 protein is accompanied by selective down‐regulation of proliferating‐cell nuclear antigen expression . Proc. Natl. Acad. Sci. USA. 88 : 1958 – 1962 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Miyashita T , Krajewski S , Krajewska M , Wang HG , Lin HK , Liebermann DA , Hoffman B , Reed JC ( 1994. ) Tumor suppressor p53 is a regulator of bcl‐2 and bax gene expression in vitro and in vivo . Oncogene. 9 : 1799 – 805 . [PubMed] [Google Scholar]
  • 78. Miyashita T , Reed JC ( 1995. ) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene . Cell. 80 : 293 – 9 . [DOI] [PubMed] [Google Scholar]
  • 79. Nguyen DM , Spitz FR , Yen N , Cristiano RJ , Roth JA ( 1996. ) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus‐mediated p53 gene transfer . J. Thorac. Cardiov. Sur. 112 : 1372 – 6 . [DOI] [PubMed] [Google Scholar]
  • 80. Nishimori H , Shiratsuchi T , Urano T , Kimura Y , Kiyono K , Tatsumi K , Yoshida S , Ono M , Kuwano M , Nakamura Y , Tokino T ( 1997. ) A novel brain‐specific p53‐target gene, BAM, containing thrombospondin type 1 repeats inhibits experimental angiogenesis . Oncogene. 15 : 2145 – 2150 . [DOI] [PubMed] [Google Scholar]
  • 81. Ohgaki H , Eibl RH , Schwab M , Reichel MB , Mariani L , Gehring M , Petersen I , Holl T , Wiestler OD , Kleihues P ( 1993. ) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system . Mol Carcinog. 8 : 74 – 80 . [DOI] [PubMed] [Google Scholar]
  • 82. Ory K , Legros Y , Auguin C , Soussi T ( 1994. ) Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation . EMBO J. 13 : 3496 – 504 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Plate KH , Breier G , Weich HA , Mennel HD , Risau W ( 1994. ) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms . Int J Cancer. 59 : 520 – 9 . [DOI] [PubMed] [Google Scholar]
  • 84. Pollack IF , Hamilton RL , Finkelstein SD , Campbell JW , Martinez AJ , Sherwin RN , Bozik ME , Gollin SM ( 1997. ) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood . Cancer Res. 57 : 304 – 9 . [PubMed] [Google Scholar]
  • 85. Polyak K , Waldman T , He TC , Kinzler KW , Vogelstein B ( 1996. ) Genetic determinants of p53‐induced apoptosis and growth arrest . Genes Develop. 10 : 1945 – 52 . [DOI] [PubMed] [Google Scholar]
  • 86. Polyak K , Xia Y , Zweier JL , Kinzler KW , Vogelstein B ( 1997. ) A model for p53‐induced apoptosis . Nature. 389 : 300 – 305 . [DOI] [PubMed] [Google Scholar]
  • 87. Rainov NG , Dobberstein KU , Bahn H , Holzhausen HJ , Lautenschlager C , Heidecke V , Burkert W ( 1997. ) Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor‐suppressor gene products on survival . J. Neuro-Oncol. 35 : 13 – 28 . [DOI] [PubMed] [Google Scholar]
  • 88. Reifenberger G , Liu L , Ichimura K , Schmidt EE , Collins VP ( 1993. ) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations . Cancer Res. 53 : 2736 – 9 . [PubMed] [Google Scholar]
  • 89. Rice CD , Baldwin NG , Biron RT , Bear HD , Merchant RE ( 1997. ) Ex vivo expansion of tumor‐draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma‐sensitized lymphocytes . J. Neuro-Oncol. 32 : 29 – 38 . [DOI] [PubMed] [Google Scholar]
  • 90. Righetti SC , Delia TG , Pilotti S , Menard S , Ottone F , Colnaghi MI , Pierotti MA , Lavarino C , Cornarotti M , Oriana S , Bohm S , Bresciani GL , Spatti G , Zunino F ( 1996. ) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin‐based chemotherapy in advanced ovarian carcinoma . Cancer Res. 56 : 689 – 93 . [PubMed] [Google Scholar]
  • 91. Rolley N , Butcher S , Milner J ( 1995. ) Specific DNA binding by different classes of human p53 mutants . Oncogene. 11 : 763 – 70 . [PubMed] [Google Scholar]
  • 92. Ropke M , Hald J , Guldberg P , Zeuthen J , Norgaard L , Fugger L , Svejgaard A , Van Der Burg , S , Nijman HW , Melief CJ , Claesson MH ( 1996. ) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild‐type p53‐derived peptide . Proc. Natl. Acad. Sci. USA. 93 : 14704 – 7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Sakamuro D , Sabbatini P , White E , Prendergast GC ( 1997. ) The polyproline region of p53 is required to activate apoptosis but not growth arrest . Oncogene. 15 : 887 – 98 . [DOI] [PubMed] [Google Scholar]
  • 94. Salcman M ( 1995. ) The natural history of low‐grade gliomas . In : Benign Cerebral Glioma , M.L.J. A , 213 – 229 , Illinois .
  • 95. Sandig V , Brand K , Herwig S , Lukas J , Bartek J , Strauss M ( 1997. ) Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death . Nat. Med. 3 : 313 – 9 . [DOI] [PubMed] [Google Scholar]
  • 96. Schlichtholz B , Legros Y , Gillet D , Gaillard C , Marty M , Lane D , Calvo F , Soussi T ( 1992. ) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot . Cancer Res. 52 : 6380 – 4 . [PubMed] [Google Scholar]
  • 97. Serrano M , Lin AW , McCurrach ME , Beach D , Lowe SW ( 1997. ) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a . Cell. 88 : 593 – 602 . [DOI] [PubMed] [Google Scholar]
  • 98. Shelling AN ( 1997. ) Role of p53 in drug resistance in ovarian cancer . Lancet. 349 : 744 – 5 . [DOI] [PubMed] [Google Scholar]
  • 99. Shin TH , Paterson AJ , Kudlow JE ( 1995. ) p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth‐stimulatory role for p53 . Mol. Cell. Biol. 15 : 4694 – 701 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Sidransky D , Mikkelsen T , Schwechheimer K , Rosenblum ML , Cavenee W , Vogelstein B ( 1992. ) Clonal expansion of p53 mutant cells is associated with brain tumour progression . Nature. 355 : 846 – 7 . [DOI] [PubMed] [Google Scholar]
  • 101. Sjögren S , Inganas M , Norberg T , Lindgren A , Nordgren H , Holmberg L , Bergh J ( 1996. ) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry . J. Natl. Canc. Inst. 88 : 173 – 82 . [DOI] [PubMed] [Google Scholar]
  • 102. Srivastava S , Wang S , Tong YA , Hao ZM , Chang EH ( 1993. ) Dominant negative effect of a germ‐line mutant p53: a step fostering tumorigenesis . Cancer Res. 53 : 4452 – 5 . [PubMed] [Google Scholar]
  • 103. Stewart N , Hicks GG , Paraskevas F , Mowat M ( 1995. ) Evidence for a second cell cycle block at G2/M by p53 . Oncogene. 10 : 109 – 15 . [PubMed] [Google Scholar]
  • 104. Sturzbecher HW , Donzelmann B , Henning W , Knippschild U , Buchhop S ( 1996. ) p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction . EMBO J. 15 : 1992 – 2002 . [PMC free article] [PubMed] [Google Scholar]
  • 105. Tada M , Iggo RD , Ishii N , Shinohe Y , Sakuma S , Estreicher A , Sawamura Y , Abe H ( 1996. ) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay . Int. J. Cancer. 67 : 447 – 50 . [DOI] [PubMed] [Google Scholar]
  • 106. Tada M , Iggo RD , Waridel F , Nozaki M , Matsumoto R , Sawamura Y , Shinohe Y , Ikeda J , Abe H ( 1997. ) Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses . Mol. Carcin. 18 : 171 – 6 . [PubMed] [Google Scholar]
  • 107. Tada M , Matsumoto R , Iggo RD , Onimaru R , Shirato H , Sawamura Y , Shinohe Y ( 1998. ) Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations . Cancer Res. 58 : 1793 – 1797 . [PubMed] [Google Scholar]
  • 108. Tenan M , Carrara F , Di Donato S , Finocchiaro G ( 1995. ) Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas . Int J Cancer. 62 : 115 – 7 . [DOI] [PubMed] [Google Scholar]
  • 109. Ueba T , Nosaka T , Takahashi JA , Shibata F , Florkiewicz RZ , Vogelstein B , Oda Y , Kikuchi H , Hatanaka M ( 1994. ) Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells . Proc. Natl. Acad. Sci. USA. 91 : 9009 – 13 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Van Meir EG , Kikuchi T , Tada M , Li H , Diserens AC , Wojcik BE , Huang H‐JS , Friedmann T , De Tribolet N , Cavenee WK ( 1994. ) Analysis of the p53 gene and its expression in human glioblastoma cells . Cancer Res. 54 : 649 – 52 . [PubMed] [Google Scholar]
  • 111. Van Meir EG , Polverini PJ , Chazin VR , Huang H‐JS , De Tribolet N , Cavenee WK ( 1994. ) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells . Nature Genet. 8 : 171 – 6 . [DOI] [PubMed] [Google Scholar]
  • 112. Van Meir EG , Roemer K , Diserens AC , Kikuchi T , Rempel SA , Haas M , Huang H‐JS , Friedmann T , De Tribolet N , Cavenee WK ( 1995. ) Single cell monitoring of growth arrest and morphological changes induced by transfer of wild‐type p53 alleles to glioblastoma cells . Proc Natl Acad Sci U S A. 92 : 1008 – 12 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Van Meyel DJ , Ramsay DA , Casson AG , Keeney M , Chambers AF , Cairncross JG ( 1994. ) p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression . J. Natl. Cane. Inst. 86 : 1011 – 7 . [DOI] [PubMed] [Google Scholar]
  • 114. Vierboom MP , Nijman HW , Offringa R , van der Voort EI , Van Hall T , van Den Broek L , Fleuren GJ , Kenemans P , Kast WM , Melief CJ ( 1997. ) Tumor eradication by wild‐type p53‐specific cytotoxic T lymphocytes . J. Exp. Med. 186 : 695 – 704 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Volpert OV , Dameron KM , Bouck N ( 1997. ) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity . Oncogene. 14 : 1495 – 502 . [DOI] [PubMed] [Google Scholar]
  • 116. Volpert OV , Tolsma SS , Pellerin S , Feige JJ , Chen H , Mosher DF , Bouck N ( 1995. ) Inhibition of angiogenesis by thrombospondin‐2. Biochem . Biophys. Res. Comm. 217 : 326 – 32 . [DOI] [PubMed] [Google Scholar]
  • 117. von Deimling A , Eibl RH , Ohgaki H , Louis DN , von Ammon K , Petersen I , Kleihues P , Chung RY , Wiestler OD , Seizinger BR ( 1992. ) p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma . Cancer Res. 52 : 2987 – 90 . [PubMed] [Google Scholar]
  • 118. von Deimling A , von Ammon K , Schoenfeld D , Wiestler OD , Seizinger BR , Louis DN ( 1993. ) Subsets of glioblastoma multiforme defined by molecular genetic analysis . Brain Pathol. 3 : 19 – 26 . [DOI] [PubMed] [Google Scholar]
  • 119. Walker KK , Levine AJ ( 1996. ) Identification of a novel p53 functional domain that is necessary for efficient growth suppression . Proc. Natl. Acad. Sci. USA. 93 : 15335 – 40 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120. Wang XW , Yeh H , Schaeffer L , Roy R , Moncollin V , Egly JM , Wang Z , Freidberg EC , Evans MK , Taffe BG , et al ( 1995. ) p53 modulation of TFIIH‐associated nucleotide excision repair activity . Nature Genet. 10 : 188 – 95 . [DOI] [PubMed] [Google Scholar]
  • 121. Watanabe K , Tachibana O , Sata K , Yonekawa Y , Kleihues P , Ohgaki H ( 1996. ) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas . Brain Pathol. 6 : 217 – 23 . [DOI] [PubMed] [Google Scholar]
  • 122. Watanabe K , Tachibana O , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Role of gemistocytes in astrocytoma progression . Lab. Invest. 76 : 277 – 84 . [PubMed] [Google Scholar]
  • 123. Werner H , Karnieli E , Rauscher FJ , LeRoith D ( 1996. ) Wild‐type and mutant p53 differentially regulate transcription of the insulin‐like growth factor I receptor gene . Proc. Natl. Acad. Sci. USA. 93 : 8318 – 23 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124. Williams AC , Miller JC , Collard TJ , Bracey TS , Cosulich S , Paraskeva C ( 1995. ) Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation . Oncogene. 11 : 141 – 9 . [PubMed] [Google Scholar]
  • 125. Yahanda AM , Bruner JM , Donehower LA , Morrison RS ( 1995. ) Astrocytes derived from p53‐deficient mice provide a multistep in vitro model for development of malignant gliomas . Mol. Cell. Biol. 15 : 4249 – 59 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Yanuck M , Carbone DP , Pendleton CD , Tsukui T , Winter SF , Minna JD , Berzofsky JA ( 1993. ) A mutant p53 tumor suppressor protein is a target for peptide‐induced CD8+ cytotoxic T‐cells . Cancer Res. 53 : 3257 – 61 . [PubMed] [Google Scholar]
  • 127. Yount GL , Haas KD , Vidair CA , Haas M , Dewey WC , Israel MA ( 1996. ) Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells . Cancer Res. 56 : 500 – 6 . [PubMed] [Google Scholar]
  • 128. Zhang YP , Xiong Y , Yarbrough WG ( 1998. ) ARF promotes mdm2 degradation and stabilizes p53 ‐ ARF‐INK4a locus deletion impairs both the rb and p53 tumor suppression pathways . Cell. 92 : 725 – 734 . [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES